Biden's Budget May Boost These 3 Biotechs

Biden's Budget May Boost These 3 Biotechs
·5 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

In President Joe Biden's first proposed budget to Congress, he requested authorization for spending increases in a number of areas. Specifically, the president proposed a new agency within the National Institutes of Health (NIH) with a directive to cure some of the most pressing diseases of our time, including Alzheimer's disease. If the budget is adopted, biotechs like Denali Therapeutics (NASDAQ: DNLI), Cassava Sciences (NASDAQ: SAVA), and Eli Lilly (NYSE: LLY) could find themselves with more resources than ever in a market that is estimated to reach $13 billion by 2028.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting